CL2007003145A1 - Composicion farmaceutica que comprende un compuestos derivado de indol y un sistema portador que comprende 10-50% de un primer solubilizante, 10-50% de un segundo solubilizante y 10-30% de un diluyente; proceso de preparacion; y forma farmaceutica. - Google Patents
Composicion farmaceutica que comprende un compuestos derivado de indol y un sistema portador que comprende 10-50% de un primer solubilizante, 10-50% de un segundo solubilizante y 10-30% de un diluyente; proceso de preparacion; y forma farmaceutica.Info
- Publication number
- CL2007003145A1 CL2007003145A1 CL2007003145A CL2007003145A CL2007003145A1 CL 2007003145 A1 CL2007003145 A1 CL 2007003145A1 CL 2007003145 A CL2007003145 A CL 2007003145A CL 2007003145 A CL2007003145 A CL 2007003145A CL 2007003145 A1 CL2007003145 A1 CL 2007003145A1
- Authority
- CL
- Chile
- Prior art keywords
- solubilizer
- indole
- diluent
- preparation process
- carrier system
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title abstract 4
- 239000002904 solvent Substances 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000003085 diluting agent Substances 0.000 title abstract 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 title abstract 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Indole Compounds (AREA)
Abstract
Composición farmacéutica que comprende un compuesto derivado de indol y un sistema portador que comprende 10-50% de un primer solubilizante, 10-50% de un segundo solubilizante y 10-30% de un diluyente; proceso de preparación; y forma farmacéutica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85556906P | 2006-10-31 | 2006-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2007003145A1 true CL2007003145A1 (es) | 2008-01-25 |
Family
ID=39345045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2007003145A CL2007003145A1 (es) | 2006-10-31 | 2007-10-30 | Composicion farmaceutica que comprende un compuestos derivado de indol y un sistema portador que comprende 10-50% de un primer solubilizante, 10-50% de un segundo solubilizante y 10-30% de un diluyente; proceso de preparacion; y forma farmaceutica. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100056520A1 (es) |
| EP (1) | EP2077834A2 (es) |
| JP (1) | JP2010508357A (es) |
| CN (1) | CN101573111A (es) |
| AR (1) | AR063746A1 (es) |
| BR (1) | BRPI0718030A2 (es) |
| CA (1) | CA2667864A1 (es) |
| CL (1) | CL2007003145A1 (es) |
| MX (1) | MX2009004611A (es) |
| PE (1) | PE20081474A1 (es) |
| RU (1) | RU2009116423A (es) |
| TW (1) | TW200824686A (es) |
| WO (1) | WO2008055146A2 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012031763A1 (en) | 2010-09-08 | 2012-03-15 | Twincore Zentrum Fuer Experimentelle Und Klinische Infektionsforschung Gmbh | Use of inhibitors of phospholipase a2 for the treatment or prevention of flavivirus infection |
| CN115867285A (zh) * | 2020-03-19 | 2023-03-28 | Ac免疫有限公司 | Tau蛋白病的剂量治疗 |
| RS65427B1 (sr) * | 2021-08-05 | 2024-05-31 | Pharvaris Gmbh | Kompozicija na bazi lipida za oralnu primenu antagonista receptora bradikinina b2 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5559158A (en) * | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| WO1999029316A1 (en) * | 1997-12-10 | 1999-06-17 | Severson, Mary, L. | Pharmaceutical compositions containing an omega-3 fatty acid oil |
| US6500853B1 (en) * | 1998-02-28 | 2002-12-31 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| US5922754A (en) * | 1998-10-02 | 1999-07-13 | Abbott Laboratories | Pharmaceutical compositions containing paclitaxel |
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| FR2803203B1 (fr) * | 1999-12-31 | 2002-05-10 | Fournier Ind & Sante | Nouvelles formulations galeniques du fenofibrate |
| PT1151755E (pt) * | 2000-05-04 | 2005-05-31 | Panacea Biotec Ltd | Composicoes farmaceuticas compreendendo a ciclosporina como substancia activa |
| HRP20040354B1 (en) * | 2001-10-19 | 2012-10-31 | Isotechnika Inc. | Novel cyclosporin analog microemulsion preconcentrates |
| JP4657605B2 (ja) * | 2001-12-03 | 2011-03-23 | ワイス・エルエルシー | 細胞質内ホスホリパーゼａ２の阻害剤 |
| EP1340497A1 (en) * | 2002-03-01 | 2003-09-03 | Novagali Sas | Self emulsifying drug delivery systems for poorly soluble drugs |
| US20050058670A1 (en) * | 2003-09-09 | 2005-03-17 | Jong-Soo Woo | Oral itraconazole composition which is not affected by ingested food and process for preparing same |
| GT200500310A (es) * | 2004-11-19 | 2006-06-19 | Compuestos organicos |
-
2007
- 2007-10-30 CN CNA2007800486499A patent/CN101573111A/zh active Pending
- 2007-10-30 TW TW096140776A patent/TW200824686A/zh unknown
- 2007-10-30 US US12/513,008 patent/US20100056520A1/en not_active Abandoned
- 2007-10-30 CL CL2007003145A patent/CL2007003145A1/es unknown
- 2007-10-30 MX MX2009004611A patent/MX2009004611A/es unknown
- 2007-10-30 BR BRPI0718030-6A patent/BRPI0718030A2/pt not_active Application Discontinuation
- 2007-10-30 WO PCT/US2007/082982 patent/WO2008055146A2/en not_active Ceased
- 2007-10-30 EP EP07868618A patent/EP2077834A2/en not_active Withdrawn
- 2007-10-30 JP JP2009535423A patent/JP2010508357A/ja active Pending
- 2007-10-30 RU RU2009116423/15A patent/RU2009116423A/ru unknown
- 2007-10-30 CA CA002667864A patent/CA2667864A1/en not_active Abandoned
- 2007-10-31 PE PE2007001500A patent/PE20081474A1/es not_active Application Discontinuation
- 2007-10-31 AR ARP070104832A patent/AR063746A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2009116423A (ru) | 2010-12-10 |
| TW200824686A (en) | 2008-06-16 |
| WO2008055146A3 (en) | 2008-10-09 |
| PE20081474A1 (es) | 2008-11-24 |
| WO2008055146A2 (en) | 2008-05-08 |
| WO2008055146A9 (en) | 2008-08-21 |
| CN101573111A (zh) | 2009-11-04 |
| BRPI0718030A2 (pt) | 2013-11-12 |
| JP2010508357A (ja) | 2010-03-18 |
| US20100056520A1 (en) | 2010-03-04 |
| CA2667864A1 (en) | 2008-05-08 |
| EP2077834A2 (en) | 2009-07-15 |
| AR063746A1 (es) | 2009-02-18 |
| MX2009004611A (es) | 2009-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2007002167A1 (es) | Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer. | |
| CL2010001426A1 (es) | Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas. | |
| JO2778B1 (en) | Certain Compounds, Compositions and Methods | |
| ATE502921T1 (de) | Substituierte indole | |
| NO20081160L (no) | Benzimidazoltiofen forbindelser | |
| EA201100300A1 (ru) | Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента | |
| UY30225A1 (es) | Composiciones farmacéuticas | |
| CL2011000936A1 (es) | Proceso de preparacion de compuestos derivados de l-alanina protegidos, utiles como intermediarios de la sintesis de compuestos moduladores opioides mu/delta. | |
| AR070736A1 (es) | Metodos y sistemas para recubrir sustratos | |
| ATE553104T1 (de) | Substituierte 1h-benzimidazol-4-carboxamide als potente parp-hemmer | |
| BRPI0922364A2 (pt) | Composto, composição farmacêutica e uso de um composto | |
| MX2010006738A (es) | Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos. | |
| MX2010006736A (es) | Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos. | |
| WO2008005877A3 (en) | Inhibitors of c-kit and uses thereof | |
| MX2011005898A (es) | Inhibidores de la proteina no estructural 5a del virus de la hepatitis c. | |
| CL2010001634A1 (es) | Compuestos derivados de nucleosidos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que los comprende; y combinacion farmaceutica. | |
| DE602007006478D1 (de) | Erkennung der verbindung einer dna-rekombination | |
| EA201101118A1 (ru) | Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина | |
| PY09010618A (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| PA8792401A1 (es) | Fenilendiaminas | |
| DOP2006000069A (es) | Nuevos compuestos farmaceuticos. | |
| CL2007003593A1 (es) | Composicion farmaceutica que comprende fluoresceina pura; procedimiento de preparacion de la fluoresceina. | |
| CL2007003145A1 (es) | Composicion farmaceutica que comprende un compuestos derivado de indol y un sistema portador que comprende 10-50% de un primer solubilizante, 10-50% de un segundo solubilizante y 10-30% de un diluyente; proceso de preparacion; y forma farmaceutica. | |
| DE112008003640A5 (de) | Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-Triazin-Derivaten | |
| CL2007003146A1 (es) | Composición farmacéutica que comprende un compuesto derivado de indol y un sistema portador que comprende 15-25% de un mejorador de la viscosidad, 5-15% de un solubilizante, 10-50% de un diluyente y 1-10% de un estabilizante; proceso de preparación; y forma de dosificación. |